The authors reported on the long-term outcomes of combining ipilimumab (anti-CTLA-4) with nivolumab (anti-PD-1) in patients with unresectable malignant pleural mesothelioma. The gene discussed is CTLA4; the disease is malignant pleural mesothelioma.